Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Prospectieve studie van nutraceutische supplementen ter ondersteuning van de haargroei bij vrouwen

10 november 2026 bijgewerkt door: Nutraceutical Wellness Inc.

Een prospectief onderzoek in één centrum naar nutraceutische supplementen ter ondersteuning van de haargroei bij vrouwen met zelf waargenomen dunner wordend haar

A single site open label interventional study evaluating currently marketed hair supplements targeting the underlying root causes of thinning hair.

Studie Overzicht

Toestand

Voltooid

Conditie

Interventie / Behandeling

Gedetailleerde beschrijving

A single site open label interventional study evaluating currently marketed hair supplements targeting the underlying root causes of thinning hair. All treatment regimens are commercially available nutraceutical hair growth supplements. 45 subjects will be enrolled into each of the 4 supplement groups. Subjects will undergo a baseline, baseline + 48 hours, 90 day, 90 day + 48 hours, 180 day and 180 day + 48 hours visit and will have compliance phone calls at Days 45 and 135. All subject data will be compared to baseline in paired comparison for each subject using a historical control.

Studietype

Ingrijpend

Inschrijving (Werkelijk)

181

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

    • California
      • Sacramento, California, Verenigde Staten, 95815
        • Integrative Skin Science and Research

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 70 jaar (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Ja

Geslachten die in aanmerking komen voor studie

Vrouw

Beschrijving

Inclusion Criteria:

  1. Females of all Fitzpatrick skin, and hair types between 18-70 years of age with self-perceived thinning, confirmed by a dermatologist.
  2. Willing and able to adhere to the same dietary lifestyles for the duration of the study.
  3. Able to understand and sign an informed consent agreement and photo release form approved by the Institutional Review Board
  4. General good health, as determined by the Investigator or qualified sub-investigator.
  5. Willing and able to attend all study visits and comply with the test product daily instructions.
  6. Willing to use a mild non-medicated shampoo and conditioner for the duration of the study (medicated shampoo and conditioner refer to any prescription shampoo or conditioner as well as any over-the counter medicated shampoo or conditioner, such as those for treatment of dandruff or promoting hair growth).
  7. Willing and able to cooperate with the requirements of the study.
  8. Able to complete and understand the various questionnaires.

Exclusion Criteria:

  1. Individuals who are pregnant, planning a pregnancy, nursing, or within 1-year post-partum.
  2. Individuals who have experienced serious complications due to COVID-19 previously or during the study as determined by the investigator.
  3. Clinical diagnosis of hair loss disorder such as alopecia areata, or scarring forms of alopecia.
  4. Individuals who have had a history of any acute or chronic disease that could interfere with or increase the risk on study participation.
  5. Individuals who have had a history of any acute or chronic medical or hair condition that could affect study results, such as a history of disordered eating.
  6. Scalp hair loss on the treatment area, due to disease, injury, or medical therapy.
  7. Current skin disease (e.g., psoriasis, atopic dermatitis, skin cancer, eczema, sun damage, seborrheic dermatitis), infection, cuts, and/ or abrasions on the scalp or condition (e.g., sunburn, tattoos) on the treatment area that, in the opinion of the Investigator or qualified sub-investigator, might put the subject at risk or interfere with the study conduct or evaluations.
  8. History of surgical correction of hair loss on the scalp (i.e., hair transplant).
  9. Use of any products or devices purported to promote scalp hair growth (e.g., finasteride or minoxidil) within the 6 months prior to the Baseline Visit.
  10. Females who have recently (within the last 6 months) started the use of hormones for birth control or hormone replacement therapy (HRT). Women currently using hormones for birth control or HRT must have been on a stable dose (6 months or longer) in order to be eligible for the study (the initiation of HRT or birth control should not have been associated with the initiation of hair loss/thinning).
  11. History of malignancy (except cutaneous squamous cell carcinoma and basal cell carcinoma) or currently undergoing chemotherapy or radiation treatments.
  12. A known history of autoimmune thyroid disease, any other thyroid disorder/abnormality or other autoimmune disorders that in the opinion of the Investigator or qualified sub-investigator may interfere with the study treatment.
  13. A known history of unstable or chronic depression or bipolar disease or any other condition that may impact the subject's participation in the opinion of the investigator or qualified sub-investigator.
  14. A known allergy to any of the ingredients in the investigational product.
  15. Utilization of low-level lasers for hair growth in the last three months.
  16. Any condition that the Investigator thinks may put the subject at risk or interfere with their participation in the study or study results.
  17. Known history of or current iron deficiency, bleeding disorders or platelet dysfunction syndrome as well as subjects receiving anticoagulant therapy or smokers with usage >20 cigarettes/day as reported by the subject.
  18. Use of any medications or medicated shampoos that are known to potentially cause hair loss or affect hair growth, as determined by the Investigator or qualified sub-investigator.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: NVT
  • Interventioneel model: Opdracht voor een enkele groep
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Nutrafol Hair Growth Supplement

4 commercially available hair growth nutraceuticals will be evaluated. Treatment groups will be assigned according to the investigator's discretion. Efficacy comparisons will not be made across treatment groups.

Hair growth supplement for women ages 18 - 44. This product will be studied in the general women population and not postpartum women.

Hair growth supplement for women ages 18 - 44

Hair growth supplement for women ages 45 - 70

Hair growth supplement for women ages 18 - 44. This treatment group may also include subjects who do not follow a plant-based diet for purposes of extending the product claims beyond the initially studied demographic of women primarily adhering to a plant-based diet

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
The percent change in hair growth rate at Day 180 relative to baseline (Day 0)
Tijdsspanne: 180 days

The percent change in hair growth rate at Day 180 relative to baseline (Day 0) using Canfield HairMetrix® non-invasive device.

180 days

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
The percent change in hair growth rate at Day 90 relative to baseline (Day 0)
Tijdsspanne: 90 Days

The percent change in hair growth rate at Day 90 relative to baseline (Day 0) as measured by the Canfield HairMetrix®.

90 Days
The change in total hair count, terminal hairs, vellus hairs, anagen, and telogen hairs compared to baseline at 90 days
Tijdsspanne: 90 days

The change in total hair count, terminal hairs, vellus hairs, anagen, and telogen hairs compared to baseline at 90 days as measured by the Canfield HairMetrix® compared to baseline.

90 days
The change in total hair count, terminal hairs, vellus hairs, anagen, and telogen hairs compared to baseline at 180 days
Tijdsspanne: 180 days

The change in total hair count, terminal hairs, vellus hairs, anagen, and telogen hairs compared to baseline at 180 days as measured by the Canfield HairMetrix® compared to baseline.

180 days
The change in terminal to vellus ratio
Tijdsspanne: 90 Days

The change in terminal to vellus ratio as measured by the Canfield HairMetrix® at 90 days compared to baseline.

90 Days
The change in terminal to vellus ratio
Tijdsspanne: 180 Days

The change in terminal to vellus ratio as measured by the Canfield HairMetrix® at 180 days compared to baseline.

180 Days
The change in anagen to telogen ratio
Tijdsspanne: 90 Days

The change in terminal to vellus ratio per cm2 as measured by the Canfield HairMetrix® at 90 days compared to baseline.

90 Days
The change in anagen to telogen ratio
Tijdsspanne: 180 Days

The change in terminal to vellus ratio per cm2 as measured by the Canfield HairMetrix® at 180 days compared to baseline.

180 Days
The change in average number of hairs per follicular unit
Tijdsspanne: 90 Days

The change in average number of hairs per follicular unit as measured by the Canfield HairMetrix® at 90 days compared to baseline.

90 Days
The change in average number of hairs per follicular unit
Tijdsspanne: 180 Days

The change in average number of hairs per follicular unit as measured by the Canfield HairMetrix® at 180 days compared to baseline.

180 Days
The change in total hair width per cm2
Tijdsspanne: 90 Days

The change in total hair width per cm2 as measured by the Canfield HairMetrix® at 90 days compared to baseline.

90 Days
The change in total hair width per cm2
Tijdsspanne: 180 Days

The change in total hair width per cm2 as measured by the Canfield HairMetrix® at 180 days compared to baseline.

180 Days
The change in mean inter-follicular distance
Tijdsspanne: 90 Days

The change in mean inter-follicular distance as measured by the Canfield HairMetrix® at 90 days compared to baseline.

90 Days
The change in mean inter-follicular distance
Tijdsspanne: 180 Days

The change in mean inter-follicular distance as measured by the Canfield HairMetrix® at 180 days compared to baseline.

180 Days
Subjective assessments of change measured with Consumer Perception Questionnaire at 90 days
Tijdsspanne: 90 Days

Subjective assessments of change in hair growth and appearance measured with Consumer Perception Questionnaire at 90 days

90 Days
Subjective assessments of change measured with Consumer Perception Questionnaire at 180 days
Tijdsspanne: 180 Days

Subjective assessments of change in hair growth and appearance measured with Consumer Perception Questionnaire at 180 days

180 Days

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Nuttige links

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

6 mei 2024

Primaire voltooiing (Werkelijk)

18 juni 2025

Studie voltooiing (Werkelijk)

18 juni 2025

Studieregistratiedata

Eerst ingediend

11 april 2024

Eerst ingediend dat voldeed aan de QC-criteria

16 april 2024

Eerst geplaatst (Werkelijk)

19 april 2024

Updates van studierecords

Laatste update geplaatst (Werkelijk)

16 november 2026

Laatste update ingediend die voldeed aan QC-criteria

10 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • NW-HGN-02

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .